Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments.
Simon Planken, Sylvia Faict, Fabienne Trullemans, Eleni Linskens, Karl Vandepoele, Ann De Becker
Author Information
Simon Planken: Department of Hematology, Universitair Ziekenhuis Brussel, Jette, BEL.
Sylvia Faict: Department of Hematology, Universitair Ziekenhuis Brussel, Jette, BEL.
Fabienne Trullemans: Department of Hematology, Universitair Ziekenhuis Brussel, Jette, BEL.
Eleni Linskens: Department of Clinical Biology, Universitair Ziekenhuis Brussel, Jette, BEL.
Karl Vandepoele: Department of Clinical Biology, Universitair Ziekenhuis Gent, Gent, BEL.
Ann De Becker: Department of Hematology, Universitair Ziekenhuis Brussel, Jette, BEL.
The introduction of chimeric antigen receptor T-cell (CAR-T cell) therapy has changed the treatment landscape of diffuse large B-cell lymphoma (DLBCL). However, the optimal treatment strategy after relapse after this therapy still needs to be elucidated. In this report, we describe the case of a 67-year-old male who relapsed after treatment with tisagenlecleucel as a third-line therapy. We present our approach to treatment after relapse, in which we tried to sustain the circulating chimeric antigen receptor T-cells. This is reflected by the kinetics of the chimeric antigen receptor T-cells during these treatments.
